Genable Technologies Ltd., a bio-pharmaceutical company developing new gene medicines to treat ‘dominant’ genetic diseases, today announced the appointment of Annette Clancy as Chairman of the Board.
Genable Technologies Ltd gene therapy product, GT038, has been granted Orphan Drug Designation by the Federal Drug Administration (FDA) in the USA for the treatment of Retinitis Pigmentosa. This is a significant milestone as it provides Genable Technologies with seven years market exclusivity once GT308 has secured regulatory approval.
Genable announced today the execution of an exclusive worldwide licensing agreement with Benitec Biopharma Ltd (ASX:BLT) for the use of Benitec's ddRNAi technology for rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO-adRP).
Genable Technologies, (Dublin, Ireland) successfully completed a new financing round for ?5m led by new investors Fountain Healthcare Partners alongside existing investors Delta Partners. This funding will support the on-going development of Genable's suppression/replacement gene therapy technology and specifically progress Genable's lead product GT038 for Retinitis Pigmentosa (RP) forward into clinical evaluation in man.
On 17th December 2010 orphan designation (EU/0/00/000) was granted by the European Medicines Agency (EMA) to Genable Technologies Ltd, Ireland, for GT038, an adeno-associated viral (AAV) based therapy containing DNA encoding an RNAi targeting rhodopsin and a replacement rhodopsin gene for the treatment of rhodopsin-linked Retinitis Pigmentosa.
Genable Technologies will present data on their novel approach for the treatment of RHODOPSIN-LINKED AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA – a leading cause of blindness - at the XVIIITH ANNUAL CONGRESS OF THE EUROPEAN SOCIETY OF GENE & CELL THERAPY in Milan this weekend.
Genable Technologies Ltd, a bio-pharmaceutical company developing new gene medicines to treat inherited blindness, has appointed two directors to its board: Dr John Monahan, founder and former Chief Executive Officer of Avigen, Inc. (NASDAQ: AVGN); and, Dr Alan Boyd, former Research and Development Director of Ark Therapeutics Ltd (LSE: Ark).
Genable Technologies, an early stage Irish biotechnology company, has raised €1.1 million in an investment round led by Delta Partners. Genable is developing gene-based therapies for the treatment of incurable inherited diseases. Its focus and world-leading position is in "dominant negative" diseases such as retinitis pigmentosa, which causes blindness. The company's technology platform provides for the suppression and replacement of genes. Developed from over 10 years of research, it is now entering into pre-clinical studies.